Case Study: Agritech Freedom to Operate: Clearing a CRISPR Crop for Launch

This agritech freedom to operate review follows a mid-size seed company preparing to commercialise a CRISPR-edited, disease-resistant row-crop variety across the United States and the European Union, and shows how a structured clearance answered two questions at once: who owns the gene-editing methods the trait depends on, and which regulator will even let the seed reach a field. It is a representative scenario – every hard figure below is a cited public statistic, and every model output is framed as what the method produces, not a disclosed client result.

The Agritech Freedom to Operate Challenge

The client’s strength was plant breeding and field agronomy, not the two decades of molecular-biology patenting its gene-edited trait sat on top of. Agritech is now one of the most heavily patented sectors in the world. WIPO’s agrifood patent landscape counts roughly 3.5 million patent families published over the past twenty years, of which AgriTech alone accounts for about 2.1 million, or 60 percent, growing at a 6.9 percent compound annual rate. Only about 12 percent of those families – some 450,000 – were ever filed outside their home office, which means a trait that is clear in one market can walk straight into a live patent the moment it crosses a border.

On top of the general agritech thicket sits the gene-editing layer. The CRISPR landscape runs to more than 23,000 patent families, dominated by genome-editing method claims, and the foundational plant-applicable Cas9 estates are controlled by a short list of institutions – the Broad Institute, the University of California Berkeley, the University of Vienna, Vilnius University, ERS Genomics and Caribou Biosciences – with Corteva holding or controlling the right to sublicense that foundational plant portfolio alongside its own Pioneer and DuPont Danisco patents. A seed company editing a crop is practising methods claimed in those estates whether or not it realises it.

And unlike a graphene or a semiconductor launch, the patent gate is not the only gate. Gene-edited crops face a regulatory freedom-to-operate question that can be more binding than any claim. In the United States, USDA APHIS’s 2020 SECURE rule had exempted certain gene-edited plants that could have arisen through conventional breeding – but on 2 December 2024 a federal court held that rulemaking arbitrary and capricious, and APHIS set aside its categorical exemptions and reverted to the pre-2020 framework. In the European Union, the new-genomic-techniques (NGT) regulation that would treat many edited plants as conventional was only adopted by the Council on 21 April 2026 and is not expected to apply until around mid-2028. The board wanted to know, before committing to seed increase and a distribution contract, both who it had to pay and who it had to convince.

How We Ran the Clearance

We ran the clearance as a sequence in which each step narrowed the set the next step had to examine, and we cleared the patent gate and the regulatory gate in parallel rather than one after the other, because in agritech the regulator can veto a launch that the patents allow.

Trait and feature claim mapping. We decomposed the product into concrete technical features – the editing nuclease and guide architecture, the delivery and transformation method, the specific edited gene and the resulting disease-resistance phenotype, and the finished variety as a propagating plant and seed – and mapped each to the classification an examiner would actually search: C12N15 for genetic engineering and vectors, C12N9 for the nuclease enzymes, and A01H for the new plant and its propagation, so nothing was cleared against a marketing label.

Foundational and trait-specific blocking patents. We split the problem into two layers. The foundational layer – the Cas9 editing method itself – we traced to the institutional estates that control it for plants. The trait layer – claims over the particular resistance gene, the edit and the phenotype – we pulled as live, in-force patents in the US and the EU, read the independent claims against the variety as built, and separated the thousands of patents that merely mention CRISPR or disease resistance from the few whose claims genuinely read on this gene, edited this way, in this crop.

Licence-hub versus bilateral assessment. Agritech CRISPR is unusual in having something close to a one-stop shop: Corteva positions itself as a single source that can sublicense the foundational Cas9 plant estates together – the same route through which third parties such as J.R. Simplot have taken CRISPR licences from Corteva and the Broad Institute. We scored whether the foundational layer could be cleared through that single sublicence and reserved bilateral negotiation for the trait-specific claims, which no hub covers.

Regulatory freedom to operate, US and EU. Running alongside the patent read, we scored the variety against the current regulatory status in each market: whether, after the December 2024 reversion, APHIS would treat it as exempt or as requiring a regulatory-status review, and whether under the adopted-but-not-yet-applicable EU NGT regulation it would fall into the NGT-1 category treated as conventional or the NGT-2 category kept under the full GMO regime with mandatory traceability and labelling.

What the Review Found

The mapping stage did most of the work on the patent side. Because the variety used one defined nuclease and one edited target gene, the candidate universe collapsed from the tens of thousands of CRISPR and agritech families to a few dozen patents whose claims plausibly read on it, and then, after a claim-by-claim read, to the foundational Cas9 layer plus two trait-specific blocking claim sets. The landscape was vast but the blocking list was short.

Crucially, the foundational layer cleared differently from the thicket a materials or semiconductor company faces. Instead of fragmented ownership with no one to pay, the foundational Cas9 plant estate is reachable through Corteva’s consolidated sublicensing route, so the editing method itself could be licensed on defined terms rather than designed around. That turned the single largest and scariest part of the landscape – the foundational gene-editing patents – from an existential threat into a line item with a price.

The genuine blockers were therefore the trait-specific claims: one over a native-gene knockout conferring the resistance phenotype, and one over a delivery-and-regeneration method in that crop. Neither carried any pool or standard obligation, so each needed a design-around decision or a bilateral negotiation, exactly as in any other sector.

The decisive finding, though, was on the regulatory gate, and it was the opposite of what the board expected. The patent path was clearable; the regulatory path was the binding constraint. After the December 2024 court ruling set aside the SECURE categorical exemptions, the US launch could no longer assume an automatic exemption and had to budget for an APHIS regulatory-status review. And in the EU the NGT regime that would have let the edit be treated as conventional will not apply until around 2028, so a near-term European launch would still fall under the full GMO authorisation, labelling and traceability regime. An agritech freedom to operate review that had stopped at the patents would have cleared a product the regulator was not yet ready to wave through.

The Outcome

The board approved a sequenced launch the analysis had costed on both gates. On the patent side, the company took a single Corteva sublicence to clear the foundational Cas9 plant estate, adopted a scoped design-around for the delivery-and-regeneration claim, and opened a bilateral discussion on the native-gene knockout claim from a documented, already-cleared position rather than under threat.

On the regulatory side, the plan put the United States first – entering the APHIS regulatory-status process early rather than assuming an exemption that no longer existed – and deferred the European launch until the NGT framework entered into application, rather than spending on a full GMO authorisation for a product that would shortly be re-classified. The two gates were sequenced so neither the licence spend nor the regulatory spend was wasted on a market that was not yet ready.

The result was a variety cleared for launch on a defensible timeline: the foundational editing method licensed on defined terms, the two trait blockers each retired by a design-around or a licence, the US regulatory path opened on the correct post-2024 footing, and the EU launch timed to the NGT regulation instead of against it – with a clearance file that documents both the patent and the regulatory position if a competitor or a holder ever challenges it.

Lessons for Any Agritech Launch

Agritech freedom to operate is a two-gate problem. A clean patent read means nothing if the regulator will not approve the plant, and a clear regulatory path means nothing if a foundational patent holder can enjoin you. In gene-edited crops the two gates move independently and on different timelines, and a clearance has to score both or it has cleared only half the risk.

CRISPR’s licence hub is the opposite of a thicket. Unlike a fragmented materials landscape with no one to pay, the foundational plant Cas9 estate can be reached through a consolidated sublicence. That makes the single scariest part of the agritech landscape – the foundational gene-editing patents – a priced line item rather than an existential unknown, and it changes the clearance from design-around to licence for that layer.

The regulator, not the patent, often sets the launch date. After the 2024 SECURE reversion in the US and with the EU NGT regime not applying until around 2028, regulatory status now drives agritech sequencing more than patent expiry does. Time the launch to the regulation and clear the patents in parallel – not the other way round.

What This Agritech Freedom to Operate Review Delivers

The deliverable was not a list of every patent that mentions CRISPR or a note that gene editing is regulated – it was a ranked, jurisdiction-tagged blocking list with a licence-or-design-around option beside each entry, a foundational-estate licensing route costed as a single sublicence, and a parallel US-and-EU regulatory read that told the board which market to launch in first and when. That is the difference between an FTO opinion a seed company can act on and a search dump that leaves the launch decision exactly where it started. See the method behind it on our freedom-to-operate analysis service page.

Why Agritech Clears Differently – Two Gates, Not One

A graphene or a semiconductor product clears on patents alone: map the claims, tag expiry and jurisdiction, design around or license, launch. Agritech adds a second, independent gate. The gene-edited plant must also clear a regulator whose rules are themselves in motion – the US set aside its gene-editing exemptions in December 2024, and the EU’s new-genomic-techniques framework will not apply until around 2028. At the same time the patent side is easier in one respect, because the foundational CRISPR estate can be licensed through a single hub rather than fought claim by claim. The regulatory overlap is closest to what life-sciences launches face: compare our cell-therapy freedom-to-operate case study and our semiconductor freedom-to-operate case study for the two contrasting shapes.

Data Sources

The market and patent data referenced above comes from:

• WIPO – Patent Landscape Report: Agrifood (Key Findings) — WIPO landscape counting about 3.5 million agrifood patent families over two decades, with AgriTech at 2.1 million (60%) and a 6.9% CAGR, and only 12% of families filed internationally.
• Swiss Federal Institute of Intellectual Property (IPI) – CRISPR Technology: Patent & Licence Landscapes on Plants (2025) — Official landscape of the plant-applicable CRISPR patent and licensing estate, documenting the foundational Cas9 holders and Corteva's consolidated sublicensing position for plant agriculture.
• Fruit Growers News – Corteva, Broad Institute license Simplot to use CRISPR-Cas9 — Concrete example of the Corteva/Broad Institute one-stop plant CRISPR-Cas9 sublicensing route through which third parties obtain foundational gene-editing rights.
• Beveridge & Diamond – USDA Reverts to Pre-2020 Framework for Genetically Engineered Organisms After California Federal Court Ruling (2024) — Analysis of the 2 December 2024 federal court ruling that found the 2020 SECURE rule arbitrary and capricious, leading APHIS to set aside its categorical gene-editing exemptions.
• European Council – New genomic techniques: Council and Parliament strike deal (4 December 2025) — Official account of the EU NGT framework, under which NGT-1 plants are treated as conventional while NGT-2 plants remain under the GMO regime; the regulation was adopted in 2026 and is expected to apply from around mid-2028.

Discuss a Similar Matter

Frequently Asked Questions